Thursday, October 9


Thursday, October 9

(The presenters of gray titles did not allow the online appearance of their lectures )


56. CANCER METABOLISM AND AUTOPHAGY

ROOM A, 08.00-12.00 – Thursday, October 9

Chair Persons: R. Clarke, J. Holst


57. INVASION AND METASTASIS

ROOM A, 13.00-16.15 – Thursday, October 9

Chair Persons: J. Carlsson, M. Schauer


58. APOPTOSIS

ROOM A, 16.30-19.15 – Thursday, October 9

Chair Persons: B. Kaina, M. I. Panagiotidis


59. NEW ANTICANCER AGENTS

ROOM B, 08.00-14.30 – Thursday, October 9

Chair Persons : A. Z. Dudek, M. Schneider

  • Kiteplatin – a potential clinical candidate showing significant activity vs. oxaliplatin-resistant colorectal cancer. J.D. Hoeschele, E. Petruzzella, N. Margiotta, G. Natile, V. Gandin and C. Marzano (Ypsilanti, MI, USA; Bari; Padova, Italy) (30’)
  • Opportunities and challenges to develop drugs for treating glioblastoma: A mechanistic prospective. A. Bhushan, A. Jain, J.C.K. Lai (Philadelphia ; Lexington ; Pocatello, USA) (30’)
  • Metal-based anticancer agents basing on TCM active ingredient oxoisoaporphine alkaloids. Z.F. Chen, Q.P. Qin, J.L. Qin, Y.C. Liu, K.B. Huang, Y. Peng, H. Liang (Guilin, P.R. China) (30’)
  • HSV1716 (SEPREHVIR): an oncolytic herpes virus for cancer therapy. L. Braidwood (Glasgow, UK) (30’)
  • Targeted drug delivery to pediatric sarcomas through proprotein convertases binding peptides. P. Jaaks, M. Roveri, V. D’Alessandro, B.W. Schäfer, P. Luciani, M. Bernasconi (Zurich, Switzerland) (20’)
  • A promising novel palladium-saccharinate complex of terpyridine against cancer stem cells. E. Ulukaya (Nilüfer, Bursa, Turkey) (15’)
  • Anticancer activity of novel Vitamin D analogs: structural and functional insights. N. Rochel (Illkirch, France)(20’)
  • Conjugation of anti-cancer drug to phage carrying anti-mica for targeting chemotherapy. A. Phumyen, S. Jantasorn, A. Jumnainsong C. Leelayuwat (Khon Kaen, Thailand) (10’)
  • Alkaloids mixture affects ENT1 and DCK gene expression in pancreatic ductal adenocarcinoma (PDAC): synergistic interaction with gemcitabine in preclinical models of PDAC. N. Funel, L.E. Pollina, G. Genova, U. Boggi, D. Campani (Pisa; Pontedera, Italy) (15’)

Chair Persons: M. I. Panagiotidis, E. Ulukaya

  • Virotherapy with VSV-INFβ for non-small cell lung cancer. M.R. Patel, B.A. Jacobson, K. Xiong, S. Tang, H. Wang, Y. Ji, A. Kratzke, S.J. Russell R.A. Kratzke (Minneapolis, MN, USA) (10’)
  • Copper(II) complexes of 5-(pyridin-2-yl)-norhydrastinine: crystal structure, cytotoxicity and interaction with DNA. K.B. Huang, Z.F. Chen, Y.C. Liu H. Liang (Guilin, P.R. China) (15’)
  • Synthesis and antitumor mechanism of a new anthracene imidazole hydrazone derivative. Y.C. Liu, H.L. Wang, S.F. Tang, Z.F. Chen, H. Liang (Guilin, P.R. China) (15’)
  • Isothiocyanates as anticancer agents in an in vitro model of human malignant melanoma. A. Sfakianos, T. Mantso, S. Tabaczar, A. Pappa, M. Panagiotidis (Edinburgh, UK; Alexandroupolis, Greece) (10’)
  • Mafosfamide and glufosfamide as new anticancer oxazaphosphorine agents. L. Mazur, M. Opydo-Chanek, M. Stojak, K. Sladowska, K. Blicharski, B. Janota, U. Niemeyer (Krakow, Poland; Bielefeld, Germany) (15’)

60. ADVANCES IN PROSTATE CANCER

ROOM B, 14.45-19.00 – Thursday, October 9

Chair Persons : K. De Meirleir, D. Sliva

Chair Persons: A. A. Sinha, M. Tarle

  • Anticancer effect of prosta caid: A research overview from laboratory to clinical response. D. Sliva, I. Eliaz (Indianapolis, IN; Santa Rosa, CA, USA) (30’)
  • Stereotactic body radiotherapy in prostate cancer: where are we going? B. De Bari, L. Lestrade, F. Alongi (Lausanne; Geneva, Switzerland; Negrar; Verona, Italy) (20’)
  • Vitamin D deficiency in patients with prostate cancer. K. Wieczorek, R.S. Braczkowski, B. Braczkowska (Katowice, Poland) (15’)
  • Prostate-specific antigen variations in Moroccan patients with histologically proven benign prostatic hyperplasia. I. Sadaoui, W. Mahfoud, H. Amrani Hassani Joutei, N. Elgnaoui, A. Seddiki, H. Benomar, S. Nadifi (Casablance, Morocco) (15’)
  • NF- κB nuclear localization and its prognostic in Moroccan patients with hormono-refractory prostate cancer. I. Sadaoui, V. Brrès, B. Péant, H. Amrani Hassani Joutei, W. Mahfoud, H. Benomar, A.-M. Mes Masson, F. Saad, S. Nadifi (Casablanca, Marocco, Montreal, QC, Canada) (15’)

61. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-15.15 – Thursday, October 9

Chair Persons: F. Lumachi, R. Nagler, D. Schiffer

Chair Persons: R. Andersson, K. Guzinska-Ustymovicz

  • Salivary tumor markers for oral and oropharyngeal cancer. R. Nagler (Haifa, Israel) (30’)
  • The Digital Cancer Patient. C. Sansom, V. Diaz-Zuccarini (London, UK) (20’)
  • Nuclear receptors in pancreatic tumorcells. C. Damaskos, T. Karatzas, I.D. Kostakis, L. Nikolidakis, A. Kostakis, G. Kouraklis (Athens, Greece) (10’)
  • Proteomics approaches to identifying proteins involved in adenoma-to-colorectal carcinoma progression. K. Dus-Szachniewicz, P. Ostasiewicz, P. Ziólkowski, M. Wozniak, B. Ziólkowska, M. Mann, J.R. Wisniewski (Wroclaw, Poland) (10’)

Chair Persons: P. Dziegiel, C. Sansom


62. RADIOTHERAPY

ROOM C, 15.30-17.30 – Thursday, October 9

Chair Persons: L. Trigo, N. Nguyen


63. ADVANCES IN BREAST CANCER

ROOM D, 8.00-12.00 – Thursday, October 9

Chair Persons: J.E. Slansky, A.M. Cimpean, G. Broich


64. ADVANCES IN BREAST CANCER

ROOM D, 13.00-17.30 – Thursday, October 9

Chair Persons: L. Hilakivi-Clarke, M. Eskelinen

Chair Persons: A. Dasu, M. Raica


65. NEW INSIGHTS IN BRAIN TUMORS
Special Symposium Organized by G. Sica and M. Jhanwar-Uniyal

ROOM E, 8.00-12.00 – Thursday, October 9

Chair Persons: G. Sica, M. Jhanwar-Uniyal


66. CANCER PREVENTION IN ASIA PACIFIC COUNTRIES
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 13.00-16.00 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip


67. TOXICOLOGY AND CANCER AETIOLOGY
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 16.15-18.30 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip


68. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 08.00-12.00 – Thursday , October 9

Chair Persons: B. Littlefield, M. Hamann

  • Defining a new protein target for the selective treatment of melanoma. W. Fenical, L. Trzoss, J. LaClair, L.V. Costa-Lotufo, P. Jimenez (San Diego, CA, USA; Fortaleza, Brazil) (40′)
  • Screening natural product libraries for cancer-selective cytotoxins. D. Demers, M. Knestrick, C. Witowski, J. Von Salm, R. Green, L. Hamel, M. Howell, C. Powell, A. Ubaldani, L. Calcul, L. Chen, D. Mitchell, Y. Ren, B. Vesely, R. Deschenes, D.E. Kyle, S. Mohapatra, S. Westerheide, J. Wu, B.J. Baker (Tampa, FL, USA) (30′)
  • Inhibition of spontaneous and induced mutagenesis by natural compounds and mixtures. P.G. Sacks, Z.L. Zhao, W. Kosinska, Z. He, M. Khmelnitsky, J.H. Kim, J.B. Guttenplan (New York, NY, USA) (15′)
  • The taccalonolides: plant derived microtubule stabilizers. S.L. Mooberry, A.L. Risinger, J. Peng, C.C. Rohena, J. Li, A.R.B. Ola, J. Kuhn (San Antonio, TX, USA) (40′)
  • Patemine A and congeners: Anticancer strategies with protein synthesis inhibitors. D. Romo (College Station, TX, USA) (40′)
  • Dietary constituents and experimental breast cancer. G. Vollmer, O. Zierau, B.M. Dietz, J.L. Bolton, G.F Pauli, D. Macejova (Dresden, Germany; Chicago, IL, USA; Bratislava, Slovak Republic) (15′)
  • A glimpse into natural product drug discovery at Eisai. M.H.D. Postema (Andover, MA, USA) (40′)

69. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 13.00-17.30 – Thursday , October 9

Chair Persons: S. Moobery, D. Romo